Zuo Li Pharmaceutical: The development work of Ling Yi Bio's Parkinson's pipeline LY-N001 is ongoing.

Jin10 data reported on September 7th that Zoli Pharmaceutical stated during an institutional survey that the research and development of Lingyi Bio's Parkinson's pipeline LY-N001 is continuing to advance, with the main preclinical research work already completed. This pipeline targets Parkinson's subtype patients associated with GBA1 gene mutations, with future goals of filing IND applications in China and the US and conducting clinical research as well as global market layout. Lingyi Bio is a company focused on the R&D of innovative drugs for single-gene genetic diseases, positioned to develop gene therapies with differentiated advantages. The company increased its investment in Lingyi Bio by 20 million yuan in April 2025.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)